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A reversible carnitine palmitoyltransferase  (CPT1)
inhibitor offsets the proliferation of chronic 
lymphocytic leukemia cells 
Chronic lymphocytic leukemia (CLL) cells display
altered lipid metabolism and utilize fatty acid oxidation
for their energy needs. We explored, on leukemic cells
exposed in vitro to activating microenvironment-mimick-
ing stimuli, the effects of a reversible inhibitor of carni-
tine-palmitoyl transferase 1A (CPT1A), a rate-limiting
enzyme for fatty acid import into mitochondria. We
found that the inhibitor, called ST1326 (Sigma-Tau IFR
S.p.A., Italy), induced mitochondrial dysfunction and cell
death specifically in activated/proliferating CLL cells, irre-
spective of TP53 alterations or chromosomal abnormali-
ties. Upregulation of Mcl-1 and Bcl-xl expression in
response to microenvironmental stimulation was
impaired by ST1326, making the activated/proliferating
cells sensitive to the BH3-mimetic ABT-199/venetoclax.
These results suggest that ST1326 could be used to
potentiate present therapies for CLL, particularly in the
case of drugs that lose efficacy on proliferating leukemic
cells.
The energy metabolism of CLL cells is nurtured not
only by glycolytic mechanisms but also, unlike normal B
lymphocytes, by fatty acid oxidation.1 A few inhibitors
of the fatty acid oxidation regulator PPARα have been
developed and tested in CLL models with promising
results.2,3 The main controlling step of fatty acid oxida-
tion, namely the transport of long fatty acids into mito-
chondria, requires the activity of CPT1. This enzyme has
been utilized as a putative target for drugs in CLL.
However, the use of irreversible CPT inhibitors, such as
etomoxir and perhexiline,4,5 has been discouraged in
clinical practice because of excessive liver and cardiac
toxicity. 
A reversible CPT1A inhibitor, (R)-N-(tetradecylcar-
bamoyl)-aminocarnitine (ST1326), developed initially for
diabetes treatment,6,7 was shown to decrease lymphoma8
and leukemia9 cell growth in preclinical studies. There is
no information available on its effects on activated/pro-
liferating CLL cells. The purpose of our investigation was
to assess the sensitivity of CLL cells to ST1326 in an envi-
ronment-mimicking context, in which leukemic cells
were challenged with activation stimuli that render them
generally refractory to current therapeutic regimens and
were responsible for disease progression. This strategy
had to be adopted considering that clonal expansion in
CLL occurs because of a close interaction of leukemic
cells with the microenvironment, causing their activation
and subsequent proliferation.
Cells from CLL patients (Online Supplementary Table S1)
were exposed to ST1326 either in the absence or in the
presence of stimuli potentially delivered by the microen-
vironment, e.g. CD40L-fibroblasts + either interleukin
(IL)-4 or IL-21, or CpG+IL-15 (in the presence of bone
marrow stromal cells in a few cases). A significant
decrease of viability was observed in CLL cells that were
stimulated in vitro compared to quiescent cells (Figure 1A,
Online Supplementary Figure S1). Cell death was preceded
by dissipation of mitochondrial transmembrane potential
(∆ψ), as demonstrated by an ST1326-induced decrease in
∆ψ observed in cells with an intact plasma membrane
(Figure 1B, Online Supplementary Figure S1). KI67/DNA
measurements showed a stimulation-induced rise of
KI67 expression in a fraction of CLL cells, followed by
the disappearance of KI67+ cells and concomitant
increase of sub-G1 events after ST1326 treatment (Figure
1C), indicating that cycling cells were more sensitive to
ST1326 than quiescent ones. Proof of the different sensi-
tivities of the non-stimulated and stimulated cell cultures
came from the observation that a 40 h pulse of ST1326
given at later stages after stimulation (i.e. when the cells
already expressed activation markers and started pro-
gressing through the G1/S checkpoint) was more cyto-
toxic than when the drug was administered at the begin-
ning of stimulation. This is at variance with other drugs
(fludarabine and ABT-199) which lost their effectiveness
if added to overtly activated CLL cells (Figure 1D). The
level of cytotoxicity did not correlate with Binet stage,
CD38 expression or IGVH mutation, but showed a
strong relationship with in vitro proliferative response to
activation stimuli (Figure 1E).
It is noteworthy that ST1326 was also effective when
proliferation was induced in the presence of bone mar-
row stromal cells (Online Supplementary Figure S1), which
are known to provide a protective microenvironment,
and in CLL samples harboring mutated TP53 or chromo-
somal abnormalities that confer chemoresistance (Online
Supplementary Table S1 and Online Supplementary Figure
S1). Interestingly, cytotoxicity was achieved at drug con-
centrations 10 times lower than concentrations needed
for the more common CPT1 inhibitor etomoxir to reach
similar effects (Online Supplementary Figure S2). The
effects were independent of the cytokine used to pro-
mote cell proliferation (IL-4 or IL-21)10 (Online
Supplementary Figure S3).
Normal B lymphocytes were less sensitive to ST1326
cytotoxicity, at the doses lethal for CLL cells (Figure 1F
for CD40L+IL-4 stimulated B cells; data not shown for
unstimulated B cells), in line with previous observations
on normal bone marrow CD34+ cells.9 Instead, cell prolif-
eration was partly inhibited, indicating a cytostatic,
rather than cytotoxic, effect of ST1326 on normal B cells. 
Apoptosis of ST1326-treated CLL cells was associated
with Bax activation and intracellular accumulation of
lipids (Online Supplementary Figure S4), which may induce
Bax activation because of their detergent properties.
Supplementation of L-carnitine partly impaired the
effects of ST1326 on lipid accumulation (Online
Supplementary Figure S4) and apoptosis (data not shown), in
line with the described target competition of the drug.6 
ST1326 decreased intracellular levels of acetylCoA, a
product of β-oxidation that fuels the Krebs cycle and 
de novo fatty acid synthesis necessary for cell proliferation
(Figure 1G). These data are concordant with previous evi-
dence that ST1326 blocks not only CPT1A but also the
activity of CACT,8 the enzyme responsible for the trans-
port of acetyl-carnitine in the cytoplasm to regenerate
acetyl-CoA. The block of fatty acid oxidation and deple-
tion of cytosolic acetyl-CoA induce a downturn in cellu-
lar energy that might account for the growth inhibiting
effects of ST1326. 
CLL cell viability and chemoresistance are sustained by
the activity of Bcl-2 family members, Mcl-1 and Bcl-xL.
Flow cytometric immunofluorescence measurements and
western blots performed on 14 samples from seven dif-
ferent CLL patients indicated a consistent decrease of the
expression of both anti-apoptotic proteins after ST1326
treatment (Figure 2A). This reduction anticipated cell
death, according to flow cytometric analysis restricted to
viable cells. 
In CLL, Mcl-1 and Bcl-xL expression is under the con-
trol of signaling pathways that include AKT11 and 
NF-κB/STAT3.12 We explored the effects of ST1326 treat-






Figure 1. ST1326 kills proliferating chronic lymphocytic leukemia cells. (A) Cell viability assessed by flow cytometric propidium iodide exclusion tests on qui-
escent or CD40L-stimulated cultures of leukemic cells from 26 CLL patients untreated or treated with ST1326 (48 h). CLL cells were obtained from peripheral
blood of CLL patients, after informed consent according to the Declaration of Helsinki. Cell activation was achieved either through CD40L-NIH-3T3 murine fibrob-
lasts + IL-4 (number of independent experiments, n=22) or IL-21 (n=4), or by CpG/ODN2006 (hTLR9 ligand) +IL-15, in the absence (n=7) or presence (n=3) of
bone marrow stromal cells (BMSC). Mean (range) values of the reduction of viability (% control) induced by 10 µM ST1326 were: 64.8 (23-94), 56.5 (50-70),
68 (48-88) and 61 (55-72) for the four different activation systems, respectively. The statistical significance of differences was evaluated by a two-sided
Wilcoxon signed rank test. *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001. (B) Mitochondrial transmembrane potential (∆Ψ) gated on the vital cell popula-
tion, as measured by DiOC6 uptake and expressed as flow cytometric fluorescence intensity of the propidium iodide-excluding cell population (with intact plas-
ma membrane), on quiescent or CD40L-stimulated cultures of leukemic cells from 26 CLL patients untreated or treated with ST1326 from the beginning of
stimulation (48 h). The number of samples for each condition is indicated. The statistical significance of differences was analyzed by a t-test two-sided Wilcoxon
signed rank test. *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001. (C) Left: flow cytometric distributions of DNA content/KI67 expression for one represen-
tative CLL sample. The CD40L-stimulated cells were tested in the absence or presence of ST1326. Gates identify KI67+ cells (above the negative-threshold dot-
ted line) and sub-G1 events (apoptotic cells and bodies, below). Right: %KI-67+ cells from CLL samples of eight CLL patients, tested with or without addition of
ST1326. (D) Cell viability in cells from two CLL patients exposed to a 40 h drug ‘pulse’, either concomitantly with CD40L-stimulation (T0) or after 48 h (T48).
The different ST1326 sensitivities of CLL cells at T0 and T48 is evident. In contrast, the effect of fludarabine (10 µM) and ABT-199 (5 nM) was remarkably
impaired if the cells were exposed to the drugs at T48. (E) Effect of ST1326 on average cell viability of CD40L-stimulated CLL cells. The patients were grouped
according to disease stage (Binet A, B or C), immunoglobulin gene mutational status [unmutated (U-CLL), <2% mutations in IGVH genes); mutated (M-CLL), ≥2%
mutations in IGVH genes], proliferative response to CD40L-stimulation (‘low’ or ‘high’ if % cells in the S+G2M cell cycle phase after 72 h stimulation was ≤ or
> 8%, respectively), and CD38 expression (cut-off: 30%). The statistical significance of differences was assessed by a two-sided Mann-Whitney test. Where no
indication is reported, the difference was not statistically significant. *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001. (F) Normal B cells from healthy volun-
teers were purified by magnetic beads (negative-selection) and activated by co-culturing with CD40L+IL-4 and treated for 48 h with 10 µM ST1326. Cell death
and proliferation were measured by flow cytometry. Viability was unaffected, while cell proliferation (% cells in S+G2M phase) was reduced in two samples. (G)
Acetyl CoA levels in leukemic cells from one CLL patient stimulated for 24 h and then exposed to ST1326 (10 µM) or 2-DG (5 mM). Data obtained by colorimetric
tests using the PicoProbe Acetyl CoA Assay Kit from AbCam (http://www.abcam.com/), are reported as mean ± SD of three experiments (two settings with CpG-
and one with CD40L-stimulus). The levels of intracellular acetyl CoA increase during CLL cell activation, and ST1326 affects the increase rate. 2-DG was used








Figure 2. ST1326 impairs stimulus-induced Mcl-1 and Bcl-XL upregulation and induces remarkable STAT3 downregulation. (A) Left: expression of the Bcl-2-fam-
ily anti-apoptotic members, Mcl-1 and Bcl-xL, in leukemic cells from four CLL patients, stimulated with CD40L+IL-4, and treated with or without ST1326 24 h after
stimulation. Middle: cumulative data for 24 and 42 h of treatment are represented in the box/whiskers graph (5th - 95th percentiles): the protein level in ST1326-
treated samples (divided by the level of the housekeeper protein) was calculated as the % of values in untreated controls. Right: protein expression evaluated by
intracellular immunofluorescence and flow cytometry (background-subtracted fluorescence) on samples from five CLL patients is illustrated as a cumulative
graph. Cells were quiescent (Q=non-stimulated) or stimulated (Act) in the absence or presence (+) of ST1326. Cells were fixed with 3% paraformaldehyde and
permeabilized with 0.1% Triton X-100 before antibody reaction. Analyses are restricted to viable cells. A non-parametric t-test was used to assess the statistical
significance of differences. *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001. (B) Left: western blots of total and phosphorylated (p) AKT (Ser473) and IKBα
(Ser32/36) and NF-κB (RelA/p65) in four samples of CLL cells stimulated with CD40L+IL-4 for 1 day and treated with ST1326 for another 24 h. Different signaling
pathways were examined in parallel gels and blots were stripped and re-probed with the indicated antibodies. Right upper panel: cumulative data calculated as
in (A). The statistical significance of differences was analyzed by a non-parametric t-test. *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001. Right lower panel:
NF-κB (RelA/p65) expression in isolated nuclei from CLL cells treated in culture as above, stained with anti-NF-κB (RelA/p65) antibody and measured by flow
cytometry. Cells were not stimulated (Q) or stimulated by CD40L+IL-4 without ST1326 (A) or with ST1326 (A+ST). Dexamethasone (DEX) treatment for 24 h (100
nM) was used as a positive control for NF-κB downregulation. (C) Left: western blots of STAT3(pan) and its phosphorylated forms pSTAT3(Tyr705) and
pSTAT3(Ser727), of total and phosphorylated JAK2 (Tyr1008) and JAK3 (Tyr980/981), and pSTAT6, in leukemic cells from four CLL patients stimulated with
CD40L+IL-4 for 1 day and treated with ST1326 for another 24 h. Different signaling pathways were examined in parallel gels and blots were stripped and re-
probed with the indicated antibodies. Middle: cumulative data for STAT3 are calculated from western blots of eight samples from six CLL patients: the average
ratio of STAT3 (unphosphorylated, phospho-Tyr705 and phospho-Ser727 STAT3) to either unphosphorylated protein level or the housekeeper are displayed as a
relative decrease of protein levels in ST1326-treated samples compared to untreated ones (set at 100). Cumulative data for JAK2 and JAK3 are calculated from
four CLL patients. A non-parametric t-test was used to assess the statistical significance of differences. *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001. Right:
expression of STAT3 and its phosphorylated forms as evaluated by intracellular immunofluorescence and flow cytometry on leukemic cells from five CLL patients,
which were either not stimulated (Q) or stimulated (Activ.) in the absence or presence of ST1326 (24-30 h). Importantly, background-subtracted data are restrict-






Figure 3. ST1326 potentiates cytotoxicity of drugs that lose effectiveness when chronic lymphocytic leukemia cells proliferate. (A) Upper: flow cytometric bivari-
ate plots of mitochondrial transmembrane potential (∆Ψ) (DiOC6 fluorescence) and cell viability (propidium iodide exclusion) of leukemic cells from one repre-
sentative CLL patient stimulated with CD40L+IL-4 and cultured with ST1326 (10 µM), ABT-199 (10 nM), or both drugs for 42 h. Middle: ST1326 and/or ABT-
199 cytotoxicity (42 h) on unstimulated (Quiescent) and CD40L-stimulated (Activated) CLL cultures. Given that ABT-199 loses efficacy on activated/proliferating
leukemic cells, the drug concentration was 10 times higher in stimulated cultures. Only stimulated CLL cells displayed increased sensitivity to drug combina-
tions, if compared to either drug alone. Lower: combination index (CI) values (at LC75 and LC90) calculated using the Chou–Talalay model (CalcuSyn software,
Biosoft, Cambridge, UK) on dose-effect profiles of activated CLL cells treated for 24 h with increasing concentrations of ST1326 (1–10 µM), ABT-199 (10–100
nM) or ST1326/ABT-199 at constant ratios. Since the CI depends on the ‘fractional effect level’, we report two levels of cytotoxicity, LC75 and LC90 (concentra-
tion lethal to 75% and 90% of CLL cells, respectively). Dotted lines indicate CI=0.9 and CI=1.1; Synergism = CI<0.9, additive effect = 0.9≤CI≤1.1 and antagonism
= CI>1.1. The original CI curve and isobolograms are reported in Online Supplementary Figure S5. (B) Upper three insets: cytotoxicity of the combination of
ST1326 (5 µM) and ibrutinib (5 µM), idelalisib (5 µM) or fludarabine (10 µM), administered for 24 h to activated CLL samples. Lower: CI values (at LC75 and
LC90) calculated using the Chou–Talalay model on dose-effect profiles of activated CLL cells treated for 24 h with increasing concentrations of ST1326 (1–20
µM), fludarabine (1–30 µM) or ST1326/fludarabine at constant ratios.
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AKT did not show a pattern of decrease similar to that
of Mcl-1/Bcl-xL. The phosphorylation of AKT was only
mildly decreased (Figure 2B), in spite of marked Mcl-
1/Bcl-xL reduction. Likewise, no clear-cut association
was evident between the drop of anti-apoptotic protein
expression and NF-κB modulation, as indicated by the
expression of the NF-κB regulators pIKBα/IKBα, and by
the levels of NF-κB in the cytoplasm (determined by
western blotting) and nucleus (determined by flow
cytometry). The changes of NF-κB expression in the
nucleus after ST1326 treatment were very variable across
patients (Figure 2B), and did not correlate with the inten-
sity of the Mcl-1/Bcl-xL decrease or with the apoptotic
response to the drug. 
Instead, STAT3 phosphorylation induced, at least in
part, by CD40-mediated activation of the IL23-IL23R
loop,13 was profoundly affected by ST1326. Expression of
both phospho(Tyr705)- and phospho(Ser727)-STAT3
was substantially reduced, with this effect being
observed well before overt apoptosis (Figure 2C).
Interestingly, total STAT3 expression was diminished as
well, possibly because of the positive feedback loop driv-
en by activated STAT3 on U-STAT3.14 Phosphorylation of
STAT6, induced by IL-4, was also remarkably reduced
after treatment with the aminocarnitine-derivative
(Figure 2C).
In the face of the striking reduction of STAT3 and
STAT6 phosphorylation in all CLL patients, the phospho-
rylation of JAK2 and JAK3, which are involved in STAT
regulation,14,15 was only very modestly and occasionally
reduced (Figure 2C), suggesting that the STAT3/6 down-
turn induced by ST1326 might be mediated only in part
by JAK2/3 downregulation. In CLL, STAT3 is also regu-
lated by NF-κB,12 which was likewise not downregulated
by ST1326. 
Altogether, it appears that the CPT1 inhibitor strongly
affects STAT3 and STAT6 activation in stimulated CLL
cells independently, at least in part, of the modulation of
JAK2/3 and NF-κB. 
STAT have a crucial role in the pathogenesis of CLL. In
particular, STAT3, which is upregulated in CLL cells and
is constitutively phosphorylated on serine residue 727,
equips CLL cells with a survival advantage and prolifera-
tion capacity.14 Thus, the data of our study may advocate
a potential benefit of ST1326 as a STAT3/STAT6-modu-
lator. It remains to be elucidated how this drug downreg-
ulates the activity of these transcription factors.
We combined the aminocarnitine derivative with the
novel BH-3 mimetic ABT-199 (venetoclax), which specif-
ically inhibits Bcl-2 and not Mcl-1/Bcl-xL, and therefore
becomes less effective when Mcl-1/Bcl-xL are upregulat-
ed. We observed significant potentiation of ABT-199
cytotoxicity by ST1326 in the proliferating CLL cultures
(Figure 3A). Combination of the CPT1A inhibitor with
more frequently used drugs showed that ST1326 did not
potentiate the effects of the kinase inhibitors idelalisib
and ibrutinib (Figure 3B), possibly because these two
drugs significantly reduced cell proliferation and thus
impaired CLL cell sensitivity to ST1326. Conversely, flu-
darabine cytotoxicity was potentiated by ST1326 (Figure
3B).
To elucidate whether the effects of ST1326/ABT-199
and ST1326/fludarabine drug combinations were syner-
gic or just additive, we performed cytotoxicity experi-
ments at multiple drug concentrations and applied the
Chou-Talalay model. The combination index and
isobolograms indicated a ‘more-than-additive’ effect for
the ST1326/ABT-199 drug combination and a remarkable
level of synergy for ST1326/fludarabine in most CLL
samples (Figure 3A,B and Online Supplementary Figures S5
and S6).
This study demonstrates, for the first time, the in vitro
cytotoxic efficacy of ST1326 against activated/proliferat-
ing CLL cells at doses that are clinically achievable.
According to results presented at the 44th Annual
European Association for the Study of Diabetes (EASD)
Meeting, the plasma levels of this aminocarnitine deriva-
tive are in the high nanomolar/low micromolar range,
particularly under fasting conditions.16 Moreover, autora-
diographic studies in rats and monkeys documented drug
accumulation in the spleen, one of the lymphoid tissues
in which CLL cells reside (unpublished data from Sigma-
Tau). Thus, the drug concentration used in our experi-
ments is not far from plasma levels and could be even
lower than the drug concentration in lymphoid organs.
Importantly, in contrast to other CPT1 inhibitors, which
cause relevant adverse side effects, ST1326 displays only
low and transient liver toxicity.7 
These observations pave the way for proposing
ST1326 as a novel agent in anti-CLL drug-combination
therapeutic regimens, particularly with drugs whose effi-
cacy is offset by cell activation and proliferation. 
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